Artículos de revistas
Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant pseudomonas aeruginosa
Fecha
2017Registro en:
Clinical Infectious Diseases, Volume 65, Issue 1, 1 July 2017, Pages 158–161
Autor
Munita, Jose M.
Aitken, Samuel L.
Miller, William R.
Perez, Federico
Rosa, Rossana
Shimose, Luis A.
Lichtenberger, Paola N.
Abbo, Lilian M.
Jain, Rupali
Nigo, Masayuki
Wanger, Audrey
Araos, Rafael
Tran, Truc T.
Adachi, Javier
Rakita, Robert
Shelburne, Samuel
Bonomo, Robert A.
Aria, Cesar A.
Institución
Resumen
A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.